Locoregional relapse-free survival
FIGURE 2 · Panel A
Panel A 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Ling-Long Tang, Lin Chen, Gui-Qiong Xu, Ning Zhang, Cheng-Long Huang, Wen-Fei Li, Yan-Ping Mao, Guan-Qun Zhou, Feng Lei, Lu-Si Chen, Shao Hui Huang, Lei Chen, Yu-Pei Chen, Yuan Zhang, Xu Liu, Cheng Xu, Yin Zhao, Ji-Bin Li, Na Liu, Fang-Yun Xie, Rui Guo, Ying Sun, Jun Ma
CA Cancer J Clin 75(3) 203-215
BACKGROUND: Nearly 90% locoregionally advanced nasopharyngeal carcinoma (LANPC) responds to induction chemotherapy (IC) with significant tumor volume shrinkage. Radiotherapy always follows IC, and reduced volume has been proposed. However, the efficacy and safety of reduced-volume radiotherapy is uncertain. METHODS: In this multi-center, noninferiority, randomized, controlled trial, patients with LANPC who completed IC were randomly assigned (1:1) to receive reduced-volume radiotherapy based on post-IC tumor volume (Post-IC group) or conventional volume radiotherapy based on pre-IC tumor volume (Pre-IC group). The primary endpoint was locoregional relapse-free survival, with a noninferiority margin of 8%. Secondary endpoints comprised adverse events, and quality of life (QoL). RESULTS: Between August 7, 2020, and May 27, 2022, 445 patients were randomly assigned to Post-IC (n = 225) or Pre-IC (n = 220) groups. The average volume receiving radical dose was 66.6 cm3 in Post-IC group versus 80.9 cm3. After a median follow-up of 40.4 months, the 3-year locoregional relapse-free survival was 91.5% in the Post-IC group versus 91.2%, with a difference of 0.3% (95% confidence interval -4.9% to 5.5%). The incidence of grade 3-4 radiation-related toxicity was lower in the Post-IC group including: acute mucositis (19.8% vs 34.1%), late otitis media (9.5% vs 20.9%) and late dry month (3.6% vs 9.5%). The Post-IC group had better QoL for global health status, physical functioning, emotional functioning, dry mouth and sticky saliva. CONCLUSIONS: In this trial, reduced-volume radiotherapy was noninferior to conventional volume radiotherapy in locoregional relapse-free survival, and was associated with lower toxicities and improved QoL. (ClinicalTrials.gov identifier NCT04384627).
1 个 Figure · 4 个 KM 面板
FIGURE 2 Kaplan–Meier curves of (A) locoregional relapse‐free survival, (B) overall survival, (C) distant metastasis‐free survival, (D) and failure–free survival in the intention‐to‐treat population. A stratified Cox proportional‐hazards model was used to calculate the hazard ratios and their associated 95% CIs. The stratified log‐rank test was used to calculate p values. All stratified analyses used the same stratification factors that were used for randomization (center and stage). CI indicates confidence interval; IC, induction chemotherapy.
FIGURE 2 · Panel A
Panel A 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 2 · Panel B
Panel B 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 2 · Panel C
Panel C 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 2 · Panel D
Panel D 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。